Skip to Content

Becton, Dickinson and Co BDX

Rating as of

Morningstar’s Analysis

Currency in USD
Is it the right time to buy or sell?
Find out with Morningstar Premium
Is it the right time to buy or sell?
Find out with Morningstar Premium

1-Star Price


5-Star Price


Economic Moat


Capital Allocation


COVID-Related Revenue Continues to Boost Becton, Dickinson Growth in the Third Quarter

Alex Morozov, CFA Regional Director

Analyst Note

| Alex Morozov, CFA |

We anticipate a moderate increase to our fair value estimate for narrow-moat Becton, Dickinson following the release of third quarter results and updated guidance for fiscal 2021. The third quarter of 2020 provided easy comparables for BD, having declined over 11% between 2019 and 2020, but the nearly 27% growth year over year for the quarter from 2020 to 2021 returned total revenue to levels in line with historical growth at $4.9 billion. We currently view BD as undervalued.

Read Full Analysis

Company Profile

Business Description

Becton, Dickinson is the world's largest manufacturer and distributor of medical surgical products, such as needles, syringes, and sharps-disposal units. The company also manufactures diagnostic instruments and reagents, as well as flow cytometry and cell-imaging systems. BD Interventional (largely the former Bard business) accounts for 23% of revenue. International revenue accounts for 44% of the company's business.

1 Becton Drive
Franklin Lakes, NJ, 07417-1880
T +1 201 847-6800
Sector Healthcare
Industry Medical Instruments & Supplies
Most Recent Earnings Jun 30, 2021
Fiscal Year End Sep 30, 2021
Stock Type Slow Growth
Employees 72,000